The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2006

Filed:

Feb. 27, 2003
Applicants:

Robert W. Stadler, Shoreview, MN (US);

Eduardo N. Warman, Maple Grove, MN (US);

James H. Ericksen, North Oaks, MN (US);

Reece W. Holbrook, Shoreview, MN (US);

Inventors:

Robert W. Stadler, Shoreview, MN (US);

Eduardo N. Warman, Maple Grove, MN (US);

James H. Ericksen, North Oaks, MN (US);

Reece W. Holbrook, Shoreview, MN (US);

Assignee:

Medtronic,Inc., Minneapolis, MN (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 5/0452 (2006.01); A61N 1/37 (2006.01);
U.S. Cl.
CPC ...
Abstract

Determining termination of an identified tachyarrhythmia episode may involve analysis of a relative decrease in tachyarrhythmia rate, a normalization of electrogram morphology criteria, or both. An implanted medical device may obtain a tachyarrhythmia rate and a morphology of a cardiac waveform. The device may compare the tachyarrhythmia rate to a threshold tachyarrhythmia rate and the morphology to a template morphology, and classify the heart beat as indicating termination of the tachyarrhythmia episode when the tachyarrhythmia rate is less than the threshold tachyarrhythmia rate, the morphology categorizes as normal, or both. For arrhythmias with no therapy delivered, observation of arrhythmia behavior at the point of termination may lead to improved classification. In addition, observation of a relative decrease in tachyarrhythmia rate immediately after therapy application can lead to application of slower but more specific criteria for redetection. Also, delivery of cardioversion shocks can be aborted upon tachyarrhythmia termination.


Find Patent Forward Citations

Loading…